Edition:
United States

MedReleaf Corp (LEAF.TO)

LEAF.TO on Toronto Stock Exchange

20.30CAD
4:00pm EDT
Change (% chg)

$0.61 (+3.10%)
Prev Close
$19.69
Open
$19.87
Day's High
$20.30
Day's Low
$19.60
Volume
950,887
Avg. Vol
658,209
52-wk High
$31.25
52-wk Low
$6.81

Summary

Name Age Since Current Position

Lloyd Segal

51 2017 Non-Executive Chairman of the Board

Eitan Popper

35 President

Neil Closner

Chief Executive Officer, Executive Director

Igor Gimelshtein

Chief Financial Officer, Corporate Secretary

Angelo Fefekos

Vice President - Clinical Affairs and Quality Compliance

Darren Karasiuk

Vice President - Strategy

Ivan Latysh

Vice President - Information Technology

Norma Beauchamp

2017 Non-Executive Director

Ronald Funk

2017 Non-Executive Director

Deborah Rosati

55 2017 Non-Executive Director

Biographies

Name Description

Lloyd Segal

Mr. Lloyd Mitchell Segal has been appointed as Non-Executive Chairman of the Board of the Company effective June 7, 2017. He is currently an Entrepreneur-in-residence at Versant Ventures, a leading global healthcare venture capital firm. Previously, Mr. Segal was a managing partner of Persistence Capital Partners and a director of Valeant Pharmaceuticals International from 2007-2014. In 2013, Mr. Segal was honored by the Financial Times as Outstanding Director of the Year. Mr. Segal also serves on the board of The GBC American Growth Fund Inc. He has previously served as a director of several public and private corporations in the U.S. and Canada, and has served as CEO of public and private companies. He served as CEO of Thallion Pharmaceuticals, a biotechnology company sold to Bellus Health in 2013; as founding CEO of Caprion Pharmaceuticals (now Caprion Proteomics), a leading healthcare CRO; and CEO of Advanced Bioconcept, an early innovator in the development and sale of novel discovery tools for life science research, which was sold to NEN Life Sciences Products (now PerkinElmer Inc.) in 1998. Mr. Segal holds a BA in politics from Brandeis University and an MBA (Hons.) from Harvard Business School.

Eitan Popper

Mr. Eitan Popper serves as President of the Company. Mr. Popper brings over 15 years of international partnerships, large-scale project development, and engineering experience to the Company’s senior executive team. Mr. Popper’s responsibilities include oversight of all infrastructure and cultivation. As part of the senior executive team he is also involved in strategic partnerships and growth opportunities. Prior to joining the Company, Mr. Popper was a Managing Partner at the MENA Investment Network Inc., a Canadian investment firm developing cross-border industrial projects in the Middle East. Previously, Mr. Popper was Vice-President of Project Development at the Merhav Group, where he was involved in the development of large-scale oil and gas, power, renewable energy, and infrastructure projects in South and Central America, Africa and the Middle East. While at Merhav, Mr. Popper served as a board member of Eltek, a leading printed circuit board manufacturer traded on NASDAQ. Mr. Popper holds a B.Sc. in Civil Engineering from the Universidad Iberoamericana in Mexico, an M.Sc. in Environmental Fluid Mechanics from Stanford University, and an MBA from the Recanati School of Business at Tel Aviv University.

Neil Closner

Mr. Neil Closner serves as Chief Executive Officer, Executive Director of the Company. Mr. Closner has been a key driver of the Company’s growth and vision. His responsibilities include oversight of all general management for the organization, strategic leadership on growth opportunities and fostering an entrepreneurial spirit throughout the Company. Mr. Closner brings nearly two decades of start-up, technology and health care experience to the MedReleaf team. Previously, he was a member of the senior leadership team at Toronto’s Mount Sinai Hospital where he served as Vice-President of Business Development. Mr. Closner began his career as a health-care focused investment banker with Salomon Smith Barney (now Citigroup) and has also served as the founder, CEO or on the board of directors for more than half a dozen technology and health-care related start-up companies. Mr. Closner is Chairman of the board of the Cannabis Canada Association, representing the majority of Licensed Producers. He also sits on the executive committee and on the board of directors of Technion Canada. Mr. Closner studied economics at the London School of Economics and Political Science in London, England, and holds a BA from McGill University and an MBA from The Wharton School at the University of Pennsylvania.

Igor Gimelshtein

Mr. Igor Gimelshtein serves as Chief Financial Officer, Corporate Secretary of the Company. He is the CFO and Corporate Secretary of the Company, providing leadership on financial matters, including capital structure, forecasting, budgeting and reporting, as well as corporate development and datadriven business optimization. Previously, he was a Vice-President at Birch Hill Equity Partners, a Canadian midmarket private equity firm. While at Birch Hill, Mr. Gimelshtein worked on the development and management of a number of the portfolio companies and potential investments across a wide range of industries, each of which was aimed at generating significant growth and value-creation. Mr. Gimelshtein played a key role in Birch Hill’s investments in companies such as Softchoice, Shred-it, DHX Media (formerly Cookie Jar Entertainment), Carmanah Design and Manufacturing, and Mastermind Toys. Prior to joining Birch Hill, Mr. Gimelshtein worked in San Francisco and New York for Union Square Advisors as an investment banker focused on the technology sector. At Union Square he evaluated and executed mergers and acquisitions and financing transactions across the software, internet and digital media, and hardware sectors. Mr. Gimelshtein is an active philanthropist, spending the majority of his volunteer time working with the executive team and board of directors of the Toronto Foundation on various initiatives. Mr. Gimelshtein holds an HBA (Ivey Scholar) from the Richard Ivey School of Business at Western University.

Angelo Fefekos

Mr. Angelo Fefekos serves as Vice President - Clinical Affairs and Quality Compliance of the Company. He is responsible for the development, implementation and oversight of the Company’s quality assurance and control systems and processes, regulatory compliance, as well as the development and design of new cannabis products. Mr. Fefekos also oversees the design and management of clinical trials, which meet standards of excellence for ethics, scientific merit and regulatory compliance. Mr. Fefekos brings over a decade of healthcare experience in quality assurance, laboratory technology and clinical management skills to the Company. Prior to joining MedReleaf, Mr. Fefekos managed a team of 40 scientific staff in the Division of Diagnostic Medical Genetics at Mount Sinai Hospital in Toronto. In this role, he was responsible for all aspects of the division’s diagnostic operations. While at Mount Sinai, Mr. Fefekos also managed Allograft Technologies, one of Canada’s largest tissue banks, and was responsible for the redesign and implementation of protocols related to the recovery, processing, distribution, sterility assurance and post-market surveillance activities of transplanted human tissues. Throughout Mr. Fefeko’s career, he has developed and implemented standardized workflow processes designed to increase patient safety. Mr. Fefekos has extensive knowledge and experience with accreditation and regulatory requirements in the production of health products, medical laboratory testing and health services. Mr. Fefekos is a member of the College of Medical Laboratory Technologists of Ontario and holds an MBA from Athabasca University.

Darren Karasiuk

Mr. Darren Karasiuk serves as Vice President - Strategy of the Company. He is responsible for business development and preparing the Company for the expected introduction of a recreational cannabis market in Canada, while ensuring that MedReleaf’s business strategy and growth plan is founded in industry-leading analytics and data-driven insights. Mr. Karasiuk brings over 15 years of insight generation, marketing strategy and public affairs experience to his role. Prior to joining MedReleaf, Mr. Karasiuk was Vice-President, Insights and Advisory at Deloitte where he was a leader in the firm’s cannabis practice, co-authoring the Deloitte Survey, a comprehensive study on the Canadian recreational cannabis marketplace. Previously, Mr. Karasiuk was Vice-President, Strategy, Corporate and Public Affairs at Environics Research, where he conducted many of Canada’s earliest studies on pharmacist and physician perceptions of medical cannabis. He has also been the Canadian associate for the Marijuana Policy Group, a leading Denver-based economic and policy consulting firm specializing in helping to shape regulated medical and recreational cannabis markets. Mr. Karasiuk’s advisory experience has focused largely on the integration of consumer and marketplace data, financial modeling, corporate strategy and behavioural science, with a view to uncovering drivers of consumer behaviour and uncovering hidden market segments, as well as informing price, brand, product portfolio, communications and public affairs strategies. Mr. Karasiuk is also experienced working within highly regulated industries including private and public healthcare, pharma, tobacco, consumer packaged goods, and energy, as well as all three levels of government. Mr. Karasiuk holds an MA from Western University and an MBA from Kellogg-Schulich.

Ivan Latysh

Mr. Ivan Latysh serves as Vice President - Information Technology of the Company. He has over 30 years of experience in information technology across multiple verticals and provides leadership for the continued development of an innovative, robust and secure information technology environment at MedReleaf. Prior to joining the Company, Mr. Latysh held a number of senior positions within the marketing and professional services industries. Most recently, he was Director of Technology at Sapient Nitro, a leading technology, marketing and insights consultancy. At Sapient-Nitro, Mr. Latysh acted as a delivery lead for e-commerce implementations for some of North America’s most well-known retail brands. Previously, Mr. Latysh was Principal Software Engineer at Infor and Chief Technology Officer at RefineData Solutions Inc. This experience has provided Mr. Latysh with a deep understanding of various technical environments, information security and software development methodologies. Throughout his career, Mr. Latysh has also effectively managed and led software development initiatives. Mr. Latysh holds an MA in Electronics Engineering and Computer Programming from Dnipropetrovsk State University, Ukraine.

Norma Beauchamp

Ms. Norma Beauchamp has been appointed as Non-Executive Director of the Company effective June 7, 2017. She is the President and Chief Executive Officer of Cystic Fibrosis Canada, as well as director of Acerus Pharmaceuticals Corporation, where she is a member of both the audit and corporate governance and nominating committees. Ms. Beauchamp brings over three decades of experience in the corporate and non-profit sectors to her role with the Company, having held senior leadership positions in Canada and Germany, including executive positions at Bayer, Sanofi, and the Canadian Foundation for Women’s Health. Ms. Beauchamp has served on the boards of St. Joseph’s Health Centre Foundation, Providence Healthcare Foundation and the Breast Cancer Society of Canada. Throughout her career she has been a patient advocate, working with patient and healthcare organizations to enhance access to care. Ms. Beauchamp has completed the University of Toronto’s Rotman School of Management Directors Education Program (ICD.D), and holds a Bachelor of Business Administration in Marketing from Bishop’s University.

Ronald Funk

Mr. Ronald Funk has been appointed as Non-Executive Director of the Company effective June 7, 2017. He brings over 30 years of experience in business and consulting to his role with the Company. Since 2009, he has managed his own consulting practice, working with clients on acquisitions, restructurings, strategy development and government relations. Mr. Funk has worked on projects in various locations around the world, with clients engaged in a range of industries, including heavily regulated consumer products such as tobacco, alcohol, and food products. Other industries in which he has consulted include retail, advanced data analytics, gaming, and real estate development. Before opening his consulting practice, Mr. Funk was employed for approximately 30 years by Rothmans, Benson & Hedges Inc., serving in various roles and capacities, including Vice President of Sales, Human Resources, Corporate Affairs and Competitive Improvement. In these senior roles, he developed and executed a number of strategies that resulted in material growth in both market share and profitability. Mr. Funk currently serves as an independent director of Carey Management Inc., a privately held business that owns Canada’s largest independent wholesale distributor. Mr. Funk has also served as the Chairman of the Ontario Convenience Stores Association and Treasurer of the Canadian Convenience Stores Association. Mr. Funk holds a Kellogg-Schulich MBA from the Kellogg School of Management and the Schulich School of Business

Deborah Rosati

Ms. Deborah E. Rosati has been appointed as Non-Executive Director of the Company effective June 7, 2017. She brings over 30 years of experience in technology, consumer, retail, private equity, and venture capital spaces to her role with the Company. Ms. Rosati has extensive knowledge and experience as a corporate director, particularly in the areas of financial and enterprise risk management, corporate strategy, transformational changes, mergers and acquisitions, corporate governance, and CEO and board succession planning. Currently, Ms. Rosati serves as a director and chair of the nominating and corporate governance committee for Sears Canada Inc., and director and chair of the audit committee for NexJ Systems Inc. She is also a co-founder and CEO of Women Get On Board, a leading member-based company that connects, promotes, and empowers women to corporate boards. She has been recognized as a Diversity 50 candidate in 2014, and as one of WXN’s Top 100 Canada’s Most Powerful Women in the corporate director award category in 2012. Ms. Rosati’s community engagements include serving as a member of the Adrenalys Advisory Council and the Advisory Council at the Goodman School of Business at Brock University, from which she holds an HBA in business administration. Ms. Rosati became a Certified Director in 2008 (ICD.D) and has been a Chartered Professional Accountant (CPA) for over 30 years. In 2009, she was named as a Fellow Chartered Professional Accountant (FCPA).